GlassScriptPhysician profile
Anwar H Hussain
NPI 1437180106
$3,935.15
in general payments reported to CMS, 2019-2025
22 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $199 · 2020: $282 · 2021: $529 · 2022: $1,240 · 2023: $858 · 2024: $828.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,621 · Education: $64.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,620.95 |
| Education | $64.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $772.25 | 2019-2024 | Farxiga, Lokelma, Atacand |
| Amgen INC. | $599.27 | 2019-2024 | Repatha |
| Janssen Pharmaceuticals, INC | $580.08 | 2020-2024 | Xarelto |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $327.89 | 2020-2024 | Lifevest |
| Boehringer Ingelheim Pharmaceuticals, INC. | $262.77 | 2019-2024 | Jardiance |
| Novartis Pharmaceuticals Corporation | $210.69 | 2020-2024 | |
| Merck Sharp & Dohme LLC | $194.95 | 2021-2023 | Verquvo |
| Tactile Systems Technology INC | $173.98 | 2023-2024 | Flexitouch Plus, Entre Plus |
| Medtronic Vascular, INC. | $140.65 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $111.70 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $88.18 | 2020-2022 | |
| Amarin Pharma, INC. | $86.39 | 2020-2021 | |
| Novo Nordisk INC | $69.93 | 2022-2024 | Ozempic, Rybelsus |
| Pfizer INC. | $53.17 | 2021-2023 | |
| Preventice Services, LLC | $46.35 | 2021 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $45.45 | 2023 | Nexletol |
| Abbott Laboratories | $43.48 | 2023 | Cardiomems |
| Abiomed | $42.60 | 2024 | Impella |
| Daiichi Sankyo INC. | $26.18 | 2023 | Injectafer |
| Regeneron Healthcare Solutions, INC. | $24.12 | 2020 | |
| Boston Scientific Corporation | $23.07 | 2022 | |
| Bardy Diagnostics, INC. | $12.00 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anwar Hussain listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.